


 Cite this: *RSC Adv.*, 2018, 8, 7080

Discovery of *N*-cyclobutylaminoethoxyisoxazole derivatives as novel sigma-1 receptor ligands with neurite outgrowth efficacy in cells†

 Hao Sun,^{‡a} Yun-Jie Wang,^{‡b} Wen-Wen Shi,^{‡a} Fan Yang,^a Jie Tang,^a Tao Pang^{*b} and Li-Fang Yu^{ID}^{*a}

Herein we reported a series of 14 novel derivatives based on the *N*-cyclobutylaminoethoxyisoxazole scaffold. *In vitro* binding studies of these compounds demonstrated their low nanomolar to subnanomolar potencies as σ_1 receptor ligands, with moderate to excellent selectivity over the σ_2 receptor as represented by compounds 17–30. The majority of the derivatives scored high (>4.7) in the CNS MPO appraisal system, indicating their high likelihood in penetrating the blood–brain barrier. A number of these compounds exhibited significant neurite outgrowth efficacy in N1E-115 neuronal cells and displayed excellent selectivity for σ_1 receptors over the selected endogenous neurotransmitter transporters, such as DAT, NET and SERT. Among the mini-series, compound 28 ($K_i \sigma_1 = 0.2$ nM, $K_i \sigma_2 = 198$ nM, CNS MPO score = 5.4) emerged as a promising selective σ_1 receptor ligand that warrants its further evaluation as a potential therapeutic for neurodegenerative diseases.

 Received 4th January 2018
Accepted 6th February 2018

DOI: 10.1039/c8ra00072g

rsc.li/rsc-advances

Introduction

Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD) are caused by the progressive loss of neuronal integrity or acute neuron injury such as stroke or trauma in the brain and spinal cord.^{1–3} Current therapeutic strategies for neurodegenerative diseases are mainly aimed to decrease CNS neuron damage or brain dysfunction by conferring neuroprotection and neurogenesis.^{4,5} Consequently, the development of effective therapeutic medicine or discovery of new biological targets with neurogenesis activities remains an urgent need in the treatment of neurodegenerative diseases.

During the past decades, various kinds of receptors, ion channels and signaling pathways associated with neurogenesis activities have been identified as potential therapeutic targets for neurodegenerative diseases. Among these, the σ_1 receptor has attracted wide attention.⁶ σ_1 receptor is one of the subtype belonging to the σ receptors family which was first discovered

by Martin in 1976.⁷ The σ_1 receptor has been cloned and encoded as a protein of 223 amino acids, and specifically localized at the mitochondrial-associated endoplasmic reticulum membrane.^{8,9} In 2016, the crystal structure of the human σ_1 receptor was reported in complex with two divergent ligands. The structure indicated that the human σ_1 receptor has a trimeric architecture with a single transmembrane domain.¹⁰ The literature reports to date indicate that σ_1 receptor is considered as chaperonin to modulate signaling pathways of ER-mitochondrion such as Ca^{2+} , K^+ , and NMDA and IP_3 receptors, playing an important role in healthy CNS functioning.^{11–13} In particular, neurogenesis efficacy of brain penetrant σ_1 receptor ligands is of a considerable interest, which has been attributed to the σ_1 receptor's role in the modulation of cellular trafficking.^{14,15} The activation of σ_1 receptor leads to the transfer of cholesterol, ceramides and essential amino acids that are essential for the growth and proliferation of the neurons, along with an increased gene expression of specific protein and synthesis of various growth factors involved in neuronal outgrowth.^{16–18} Furthermore, neurogenesis function was reported to be subdued in the hippocampus of σ_1 receptor-knockout animals.¹⁹

An increasing number of σ_1 receptor ligands that stimulate neurite outgrowth in cellular screening models have been reported to date. Pentazocine (1) is a classical σ_1 receptor ligand, capable of enhancing the neurite outgrowth in PC-12 cellular model caused by the activation of σ_1 receptor and this activity was antagonized by NE-100 (2), a σ_1 receptor antagonist.²⁰ Ruscher *et al.* reported that the cortical neurons outgrowth upon treatment with SA4503 (3) could be prevented with σ_1

^aShanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, China. E-mail: lfyu@sat.ecnu.edu.cn; Tel: +86-021-622-31385

^bJiangsu Key Laboratory of Drug Screening, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, PR China. E-mail: tpang@cpu.edu.cn; Tel: +86-25-832-71043

† Electronic supplementary information (ESI) available: Spectrum of the corresponding compounds (¹H and ¹³C NMR of all final compounds). See DOI: 10.1039/c8ra00072g

‡ These authors contributed equally.






Fig. 1 Representative σ_1 receptor ligands.

receptor silencing.¹⁶ In addition, some reports in the literature suggested that the neuronal outgrowth activity by σ_1 receptor activation is synergistic with some growth factors. PRE-084 (4) is an example of high affinity σ_1 receptor ligand that can enhance neurite outgrowth and elongation induced by NGF or EGF in PC12 cells.²¹ Subsequently, PRE-084 could enhance the survival of the motoneurons and improve locomotor function in murine models of ALS.²² RC-33 (5), as a σ_1 receptor ligand, also exhibited the neurite outgrowth effects and good *in vitro* metabolic stability.^{23–25} The (*R*)-enantiomer of RC-33 (6) has been selected as a lead compound for studies in multiple sclerosis.²⁶ Therefore, the development of novel, brain-penetrant σ_1 receptor ligands with neurogenesis efficacy could find some therapeutic use for neurodegenerative diseases (Fig. 1).

In our preliminary work in the σ receptors drug discovery, we developed a series of alkoxyisoxazole derivatives that were found to be σ_1 receptor ligands with high affinity and selectivity over the σ_2 receptor.²⁷ Based on this work,²⁷ we further screened some of the most potent derivatives in a cellular model of neurite outgrowth. During the course of this investigation, alkoxyisoxazole 7 exhibited synergistic neurite outgrowth effects at a level similar to that of the positive control RC-33 (Fig. 2). Encouraged by this finding, we performed further structure–activity relationship (SAR) studies on this scaffold, incorporating *N*-cyclobutylaminoethoxy linker that was hypothesized to be a crucial structural element for neurite outgrowth. With 7 as the starting compound, herein we reported our continued efforts in the SAR




Fig. 2 The potential effect of compound 7 (10 μ M) and RC-33 (10 μ M) on NGF (2.5 ng mL^{−1})-induced neurite outgrowth model in PC12 cells. ^aSee Experimental section. Each histograms represent the mean \pm SEM of at least five different experiments. Statistically significant differences: ***p* < 0.01 vs. control using NGF alone.

studies of the *N*-cyclobutylaminoethoxyisoxazole as σ_1 receptor ligands and their cellular evaluation in neurite outgrowth assay.

Results and discussion


Chemistry

The synthesis of the new compounds was accomplished as shown in Scheme 1. The starting material 8 or 9 underwent a Mitsunobu reaction with previously reported methyl 3-hydroxyisoxazole-5-carboxylate (10) to obtain the intermediate esters 11 and 12. Lithium borohydride reduction afforded the alcohols 13 and 14, respectively, which were converted to the corresponding iodides 15 and 16 using iodine, triphenylphosphine and imidazole as a base. Subsequent reaction of the iodides with phenol or substituted phenols under alkaline conditions gave the Boc-protected isoxazole intermediates. Finally, treatment with hydrogen chloride and reductive amination with cyclobutanone and sodium cyanoborohydride resulted in final compounds 17–30. All final compounds were recrystallized by HCl/ethyl acetate as hydrochloride salts.

Radioligand binding studies at σ_1 and σ_2 receptors.²⁸

In this study, [³H] pentazocine and [³H]DTG (6) were used as the radioligands at σ_1 and σ_2 receptors. The binding affinity assays of compounds 17–30 are shown in Table 1. Firstly, we examined the effects of changing the substituents on the benzene ring. 3-Methyl substituted compound 27 retained high affinity to parent compound 7 at σ_1 receptor but a 3-fold increase in the binding affinity for σ_2 receptor. Compound 26 with a 3-trifluoromethyl substituent showed similar affinity for σ_1 receptor and significantly decreased selectivity over the σ_2 receptor when compared with compound 7. Mono-halogen substitution on the benzene ring exemplified by compounds 17–20 generally retained affinity for σ_1 receptor compared with compound 7. However, all of these mono-halogen substituted derivatives also exhibited subdued selectivity over the σ_2 receptor. Notably, the 3-bromo substituted compound 19 displayed a better selectivity (K_i σ_2 / K_i σ_1 = 131) than the 4-bromo substituted compound 20. The derivatives 21–25 also maintained similar high affinities for the σ_1 receptor upon incorporation of two halogen atoms on the benzene ring. However, this is also accompanied with higher binding affinity to the σ_2 receptor. Among the disubstituted compounds, 3,5-dichloro substituted compound 24 showed a 4-fold decreased affinity for σ_1 receptor and more than 10-fold increased binding affinity for σ_2 receptor. Next, we examined the effects of removing the methyl group on the basic nitrogen atom. Gratifyingly, compound 28 showed a high affinity for σ_1 receptor (K_i σ_1 = 0.2 nM) and excellent selectivity on σ_2 receptor (K_i σ_2 = 198 nM). Compound 29 with a 3-chloro substituted benzene ring also exhibited high binding affinity for σ_1 receptor (K_i σ_1 = 0.4 nM) but slightly lower selectivity over σ_2 receptor (K_i σ_2 = 64.3 nM). Compound 30 was a by-product obtained during the synthesis of compound 28, which showed a decreased binding affinity and selectivity indicating an unfavourable steric repulsion by the cyclobutyl group. In summary, except for compound 30, most of the derivatives





Scheme 1 ^aReagents and conditions: (a) methyl 3-hydroxyisoxazole-5-carboxylate (**10**), diisopropyl azodicarboxylate, PPh_3 , THF, 0°C to rt; (b) LiBH_4 , THF, 0°C to rt; (c) I_2 , PPh_3 , imidazole, CH_2Cl_2 , 0°C to rt; (d) phenol, or substituted phenol, K_2CO_3 , DMF, rt; (e) HCl/EtOAc , rt; (f) cyclobutanone, $\text{Na}(\text{CN})\text{BH}_3$, $\text{CH}_3\text{CO}_2\text{H}$, CH_3OH , rt.

exhibited high binding affinities for σ_1 receptor ($K_i \sigma_1 < 10 \text{ nM}$). However, all the benzene ring substituted derivatives showed various degree of decreased selectivity over the σ_2 receptor, implying that the non-substituted benzene ring was a crucial structural element for selectivity. The results for the secondary amines **28** and **29** indicate that the hydrogen bond donor on basic nitrogen atom was beneficial for increased binding affinity to the σ_1 receptor.

Blood–brain barrier permeability studies by CNS MPO

In this study, all of the novel σ_1 receptor ligands were tested their blood–brain barrier permeability by using the central

nervous system multiparameter optimization (CNS MPO) desirability tool which was reported by Travis T. Wager *et al.*^{29,30} In CNS MPO appraisal system, six structural properties of candidates would be used such as Clog *P*, Clog *D*, MW, TPSA, HBDs and pK_a that were determined as important factors in the BBB permeability. Each property was valued between 0 to 1 and weighted equally. Final collective score ranged from 0 to 6, with the higher scores of CNS MPO correlating with desirable brain permeability. Through the analysis of CNS MPO scores on more than hundreds of the drugs and original candidates acting on the CNS, a majority of them had CNS MPO desirability scores greater than 4.³⁰ As showed in Table 2, majority of the newly

Table 1 Binding affinities of derivative at σ_1 and σ_2 receptors^a

Compound	R_1	R_2	R_3	R_4	$K_i \sigma_1$ (nM)	$K_i \sigma_2$ (nM)	Selectivity ($K_i \sigma_2/K_i \sigma_1$)
7^b	$-\text{CH}_3$	$-\text{H}$	$-\text{H}$	$-\text{H}$	1.8 ± 0.2	307 ± 56	171
17	$-\text{CH}_3$	$-\text{F}$	$-\text{H}$	$-\text{H}$	1.9 ± 0.0	91.5 ± 7.5	48
18	$-\text{CH}_3$	$-\text{H}$	$-\text{F}$	$-\text{H}$	0.9 ± 0.1	78.5 ± 19.5	87
19	$-\text{CH}_3$	$-\text{Br}$	$-\text{H}$	$-\text{H}$	0.8 ± 0.1	105 ± 21	131
20	$-\text{CH}_3$	$-\text{H}$	$-\text{Br}$	$-\text{H}$	5.5 ± 1.3	86.6 ± 16.8	16
21	$-\text{CH}_3$	$-\text{F}$	$-\text{F}$	$-\text{H}$	1.7 ± 0.3	153 ± 37	90
22	$-\text{CH}_3$	$-\text{F}$	$-\text{H}$	$-\text{F}$	2.4 ± 1.2	57.0 ± 20.1	24
23	$-\text{CH}_3$	$-\text{Cl}$	$-\text{Cl}$	$-\text{H}$	3.2 ± 1.6	36.0 ± 9.7	11
24	$-\text{CH}_3$	$-\text{Cl}$	$-\text{H}$	$-\text{Cl}$	7.8 ± 3.2	22.8 ± 11.1	3.0
25	$-\text{CH}_3$	$-\text{Cl}$	$-\text{F}$	$-\text{H}$	1.3 ± 0.4	32.0 ± 6.0	25
26	$-\text{CH}_3$	$-\text{CF}_3$	$-\text{H}$	$-\text{H}$	4.0 ± 1.2	38.0 ± 2.0	9.5
27	$-\text{CH}_3$	$-\text{CH}_3$	$-\text{H}$	$-\text{H}$	4.2 ± 1.9	124 ± 68	29.5
28	$-\text{H}$	$-\text{H}$	$-\text{H}$	$-\text{H}$	0.2 ± 0.0	198 ± 64	990
29	$-\text{H}$	$-\text{Cl}$	$-\text{H}$	$-\text{H}$	0.4 ± 0.1	64.5 ± 13.2	161
30		$-\text{H}$	$-\text{H}$	$-\text{H}$	16.0 ± 5.0	53.5 ± 0.5	3.3

^a See Experimental section. Radioligands: σ_1 : [^3H](+)-pentazocine; σ_2 : [^3H] DTG (ditolylguanidine). Evaluation platform: σ_1 : Guinea pig homogenate; σ_2 : PC12 cells. ^b The K_i values for compound **7** are cited from the literature.²⁷ Data are expressed as the mean \pm SEM and each performed from three independent experiments.



Table 2 CNS MPO scores of compound 7 and all the derivatives^a

Compound	Clog <i>P</i>	Clog <i>D</i>	MW	TPSA	HBDs	p <i>K</i> _a	CNS MPO scores ^b
7	3.27	2.08	302.37	43.29	0	8.89	5.4
17	3.55	2.18	320.36	43.29	0	8.89	5.2
18	3.44	2.17	320.36	54.15	0	8.94	5.3
19	4.27	2.17	381.07	43.29	0	8.89	4.7
20	4.27	3.11	381.27	43.29	0	8.89	4.2
21	3.68	2.22	338.35	43.29	0	8.89	5.1
22	3.75	2.33	338.35	43.29	0	8.89	5.0
23	4.77	3.47	371.26	43.29	0	8.89	3.9
24	4.89	3.75	371.26	43.29	0	8.89	3.7
25	4.32	3.15	354.80	43.29	0	8.89	4.3
26	4.40	3.14	370.37	43.29	0	8.89	4.2
27	3.77	2.53	316.18	43.29	0	8.89	4.9
28	2.68	0.86	288.15	52.08	1	8.94	5.4
29	3.52	1.68	322.11	52.08	1	8.94	5.2
30	3.64	1.97	342.19	43.29	0	8.75	5.3

^a The data sources and explanations. Clog *P*: calculated partition coefficient; Clog *D*: calculated distribution coefficient at pH 7.4; MW: molecular weight; TPSA: topological polar surface area; HBDs: number of hydrogen-bond donors; p*K*_a: most basic center. The calculated physicochemical properties of the derivatives were obtained using standard commercial software: ACD/Laboratories, version 6.0 for Clog *P*, p*K*_a, HBDs and Clog *D* at PH 7.4, ChemBioDraw, version 14.0 for MW and TPSA. ^b Last CNS MPO scores were calculated by the tools reported by Travis T. Wager *et al.*³⁰

synthesized alkoxyisoxazoles obtained CNS MPO scores greater than 4. In particular, compound 28 scored the highest CNS MPO scores (5.4), in addition to the observed high binding affinities at σ 1 receptor (Table 1).

Neuritogenesis studies in N1E-115 cells

Following the radioligand binding studies and CNS MPO calculations, all of the synthesized derivatives were further tested in cellular neuritogenesis studies. In this study, N1E-115 neuronal cells were used as a screening platform for assessing the neuritogenesis effects of candidate compounds.^{31,32} All the derivatives and positive control (compound 7 and RC-33) were assessed at 10 μ M concentration in DMSO, and vehicle group using DMSO alone. The test results are shown in Fig. 3. Gratifyingly, a large proportion of the drug administration significantly increased the average neurite length of N1E-115 cells at 10 μ M concentration *vs.* vehicle group, suggestive of

a neuritogenesis effect. Through the analysis of test results, most of the disubstituted derivatives such as compound 22–25 exhibited greater neuritogenesis efficacy when compared with vehicle control. The 4-fluoro substituted compound 18 and 3-trifluoromethyl substituted compound 26 displayed better efficacy than other mono-substituted compounds. The higher efficacies observed for compounds 28 and 29 indicated that the secondary amine moiety was beneficial for promoting neuritogenesis efficacy within this series. Particularly, we obtained six compounds (18, 22, 24, 25, 28 and 29) that showed preferable neurite outgrowth effects compared to the parent compound 7 and positive control RC-33 in N1E-115 neuronal cells.

Table 3 Binding affinities of selected compounds at NET, DAT, and SERT^a

Compound	<i>K</i> _i , DAT (nM)	<i>K</i> _i , NET (nM)	<i>K</i> _i , SERT (nM)	<i>K</i> _i , σ 1 (nM)
GBR12909	8.8 \pm 3.8 ^b	—	—	—
Desipramine	—	2.5 \pm 0.4	—	—
Amitriptyline	—	—	5.4 \pm 0.9	—
7	NA ^c	NA	NA	1.8 \pm 0.2
18	5631 ^d	NA	NA	0.9 \pm 0.1
22	>10 000	2878	NA	2.4 \pm 1.2
24	1811	1606	NA	7.8 \pm 3.2
25	>10 000	1780	NA	1.3 \pm 0.4
28	NA	7102.5	NA	0.2 \pm 0.0
29	1518	600.5	NA	0.4 \pm 0.1

^a See Experimental section. DAT: dopamine transporter; NET: norepinephrine transporter; SERT: serotonin transporter. Radioligands: DAT: [³H] WIN35428; NET: [³H] nisoxetine; SERT: [³H] citalopram. ^b The *K*_i values for GBR12909, desipramine, amitriptyline and compound 7 are cited from the literature.²⁷ ^c NA: not active, defined as <50% binding in the primary assay at 10 μ M. *K*_i values were determined for those targets where the binding efficacy at 10 μ M was greater than 50%. ^d Data are expressed as average of *K*_i values and each performed from three independent experiments.




Fig. 3 Neurite outgrowth effects of all derivatives in N1E-115 neuronal cells. ^aSee Experimental section. Each histograms represent the mean \pm SEM of at least five different experiments. Statistically significant differences: **p* < 0.05, ***p* < 0.01, ****p* < 0.001 *vs.* control (CN) using DMSO alone.



Selectivity studies at selected neurotransmitter transporters

In our previous work, we found that some derivatives based on the alkoxyisoxazole scaffold not only bind to σ_1 receptor but also to common neurotransmitter transporters, such as DAT, NET and SERT.^{27,33} In order to exclude the potential interference of other receptor pathways to the observed neuritogenesis efficacy, we assessed the binding affinities of compounds **7**, **18**, **22**, **24**, **25**, **28** and **29** at the biogenic amine transporters (NET, DAT, and SERT). Gratifyingly, no appreciable binding affinity was observed for these transporters using 10 μ M concentration of tested compounds. This set of results indicated that the selected compounds had excellent selectivity for σ_1 receptor over DAT, NAT and SERT (Table 3).

Conclusions

In summary, 14 novel derivatives based on the *N*-cyclobutylaminoethoxyisoxazole scaffold were designed and synthesized. Most of the derivatives showed potent binding affinities to the σ_1 receptor ($K_i < 10$ nM) and good selectivity over the σ_2 receptor in radioligand binding tests. CNS MPO scores were calculated for predicting their blood–brain barrier permeability and the results showed most of derivatives obtained favourable CNS MPO scores greater than 4. All of the compounds were assessed for their neurite outgrowth efficacy in N1E-115 cells. Compounds **18**, **22**, **24**, **25**, **28** and **29** exhibited significant neuritogenesis effects at 10 μ M concentration *vs.* vehicle group and superior efficacy of increasing the average neurite length compared with compound **7** and RC-33. Moreover, compounds **18**, **22**, **24**, **25**, **28** and **29** showed great selectivity for σ_1 receptor over DAT, NET, and SERT transporters. Among these derivatives, compound **28** was found as the most promising compound with excellent *in vitro* binding profile (K_i σ_1 = 0.2 nM, K_i σ_2 = 198 nM), high CNS MPO score (5.4) and significant neuritogenesis efficacy, which will be further developed as potential therapeutics for neurodegenerative diseases.

Experimental section

Chemistry

General methods. Unless otherwise specified, commercial reagents and solvents were all of analytical grade or of chemical purity (>99%). Anhydrous THF was obtained by distillation over sodium wire, respectively. All reactions were run under a nitrogen atmosphere and all reaction vessels were oven-dried. The TLC was performed on silica gel GF254. Column chromatographic purification was carried out using silica gel (200–300 mesh). ^1H and ^{13}C NMR spectra were recorded on a Bruker Advance III 400 spectrometer at 400 MHz (^1H) and 101 MHz (^{13}C). Chemical shifts are reported in δ (ppm) using the δ 0 signal of tetramethylsilane (TMS) as internal standards. High resolution mass spectra were performed using a Bruker ESI-TOF high-resolution mass spectrometer. Purities of final compounds were established by Agilent 1200 HPLC system with a ZORBAX Eclipse XDB-C18 column, with detection at 220 or 254 nm on a variable wavelength detector G1365D; flow rate =

1.4 mL min^{−1}; gradient of 0 to 100% methanol in water (both containing 0.05 vol% of TFA) in 25 min.

General procedure for the Mitsunobu reaction (method A). Diisopropyl azodicarboxylate (2.0 mmol) was added dropwise into a stirred solution of **8** or **9** (1.0 mmol), **10** (1.2 mmol), and PPh₃ (2.0 mmol) in anhydrous THF (20 mL) at 0 °C under the nitrogen. After stirring overnight at rt, the solvent was evaporated, and the residue was dissolved in EtOAc (30 mL). The organic layer was washed with water (20 mL) and brine (15 mL), dried over Na₂SO₄ and evaporated *in vacuo*. The residue was purified by flash chromatography to give the product.

General procedure for the reduction reaction (method B). LiBH₄ (4 mmol) was added into a solution of compound **11** or **12** (0.8 mmol) in anhydrous THF (20 mL) with ice cooling under nitrogen. After stirring overnight at rt, the reaction was quenched by saturated aqueous NH₄Cl solution with ice cooling. The mixture was extracted with EtOAc (3 × 30 mL). The organic layer was washed with water (20 mL) and brine (15 mL), dried over Na₂SO₄ and evaporated *in vacuo*. The residue was purified by flash chromatography to give the product.

General procedure for the preparation of iodides (method C). I₂ (1.2 mmol) was added into a stirred solution of compound **13** or **14** (0.7 mmol), imidazole (2.0 mmol), and PPh₃ (1.2 mmol) in anhydrous DCM (10 mL) with ice cooling under nitrogen. After reacting completely at rt, the solvent was evaporated. The residue was purified by the flash chromatography to give the product.

General procedure for the preparation of phenyl ethers (method D). K₂CO₃ (6.0 mmol) was added into a stirred solution of compound **15** or **16** (1.0 mmol) and phenol or substituted phenol (2.0 mmol) in anhydrous DMF (4 mL) under nitrogen. After stirring overnight at rt, water (30 mL) was added. The mixture was extracted with EtOAc (2 × 30 mL), and the combined organic layers were washed with water (3 × 20 mL) and brine (20 mL), dried over Na₂SO₄ and evaporated *in vacuo*. The residue was purified by the flash chromatography to give the phenyl ether product.

General procedure for the deprotection (method E). HCl/EtOAc (4 mol L^{−1}, 2 mL) was added into a stirred solution of the *N*-Boc protected intermediates (1.0 mmol) in CH₂Cl₂ (5 mL) under nitrogen with ice cooling. The mixture was stirred overnight at rt. After the solvent was evaporated, the residue was by ether (20 mL). The resulting solid was filtered to give the HCl salt.

General procedure for the reductive amination (method F). NaCNBH₄ (0.6 mmol) was added into a stirred solution of compound primary or secondary amine (0.4 mmol), cyclobutanone (0.5 mmol) and acetic acid (0.05 mL) in CH₃OH (10 mL) at rt under nitrogen. After stirring overnight at rt, the solvent was evaporated and the residue was extracted with EtOAc (3 × 10 mL). The combined organic layer was washed with water (20 mL) and brine (15 mL), dried over Na₂SO₄ and evaporated *in vacuo*. The residue was purified by flash chromatography. To a solution of the *N*-alkyl compound in CH₂Cl₂ (3 mL) was added HCl/EA (4 mol L^{−1}, 1 mL) under N₂ with ice cooling. The mixture was stirred overnight at rt. The solvent was evaporated to give the HCl salt.



Methyl 3-hydroxyisoxazole-5-carboxylate (10). Dimethyl 2-butyndioate was added into a solution of *N*-hydroxyurea (0.05 mol) and DBU (0.06 mol) in methanol (50 mL) at 0 °C under nitrogen. The reaction was stirred at 0 °C for 1 h. After stirred overnight at rt, the solvent was evaporated *in vacuo* and the residue was dissolved into water (20 mL) and acidified to pH 1 with 1 N hydrochloric acid. The mixture was extracted with diethyl ether (3 × 25 mL), dried over Na₂SO₄ and evaporated *in vacuo*. The resulting solid was recrystallized from chloroform to give the product. White solid; yield 41%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.89 (s, 1H), 6.75 (s, 1H), 3.87 (s, 3H).

Methyl 3-(2-((*tert*-butoxycarbonyl)amino)ethoxy)isoxazole-5-carboxylate (11). This compound was obtained from compounds **8** and **10** employing method A. White solid, yield 85%. ¹H NMR (400 MHz, CDCl₃) δ 6.55 (s, 1H), 4.35 (t, *J* = 5.0 Hz, 2H), 3.95 (s, 3H), 3.63–3.46 (m, 2H), 1.45 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 171.3, 160.4, 157.0, 155.7, 100.7, 77.2, 69.7, 52.9, 39.7, 28.3.

Methyl 3-(2-((*tert*-butoxycarbonyl)(methyl)amino)ethoxy)isoxazole-5-carboxylate (12). This compound was obtained from compounds **9** and **10** employing method A. White solid; yield 91%. ¹H NMR (400 MHz, CDCl₃) δ 6.54 (s, 1H), 4.41 (m, 2H), 3.95 (s, 3H), 3.63 (m, 2H), 2.94 (s, 3H), 1.45 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 171.3, 160.3, 157.0, 155.5, 100.7, 79.8, 68.6, 52.8, 47.8, 35.3, 28.3.

***tert*-Butyl(2-((5-(hydroxymethyl)isoxazol-3-yl)oxy)ethyl)carbamate (13).** This compound was obtained from **11** employing method B. Colorless oil; yield 90%. ¹H NMR (400 MHz, CDCl₃) δ 5.89 (s, 1H), 4.94 (s, 1H), 4.64 (s, 2H), 4.28 (t, *J* = 5.0 Hz, 2H), 3.56–3.47 (m, 2H), 2.48 (br, 1H), 1.44 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 173.0, 171.5, 156.0, 93.1, 79.8, 69.0, 56.5, 39.8, 28.3.

***tert*-Butyl(2-((5-(hydroxymethyl)isoxazol-3-yl)oxy)ethyl)(methyl)carbamate (14).** This compound was obtained from **12** employing method B. Colorless oil; yield 88%. ¹H NMR (400 MHz, CDCl₃) δ 5.81 (s, 1H), 4.55 (s, 2H), 4.25 (t, *J* = 5.2 Hz, 2H), 3.57 (br, 1H), 3.52 (t, *J* = 5.2 Hz, 3H), 2.85 (s, 3H), 1.37 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 172.0, 170.5, 154.7, 92.2, 79.0, 67.0, 55.7, 47.0, 34.2, 27.1.

***tert*-Butyl(2-((5-(iodomethyl)isoxazol-3-yl)oxy)ethyl)carbamate (15).** This compound was obtained from **13** employing method C. Yellow oil; yield 57%. ¹H NMR (400 MHz, CDCl₃) δ 5.92 (s, 1H), 4.91 (s, 1H), 4.28 (m, 2H), 4.26 (s, 2H), 3.54–3.47 (m, 2H), 1.44 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 171.6, 169.6, 155.7, 94.0, 79.6, 69.2, 39.8, 28.4, –12.7.

***tert*-Butyl(2-((5-(iodomethyl)isoxazol-3-yl)oxy)ethyl)(methyl)carbamate (16).** This compound was obtained from **14** employing method C. Yellow oil; yield 61%. ¹H NMR (400 MHz, CDCl₃) δ 5.93 (s, 1H), 4.34 (m, 2H), 4.28 (s, 2H), 3.60 (m, 2H), 2.94 (s, 3H), 1.45 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ 171.5, 169.5, 155.5, 94.0, 79.7, 68.1, 47.9, 35.2, 28.4, –12.6.

***N*-(2-((3-(3-Fluorophenoxy)methyl)isoxazol-3-yl)oxy)ethyl)-*N*-methylcyclobutanamine hydrochloride (17).** This compound was obtained from **16** employing methods D, E and F. White solid; yield 33%; purity 94.6%. ¹H NMR (400 MHz, D₂O) δ 7.31 (m, 1H), 6.80 (m, 3H), 6.26 (s, 1H), 5.13 (s, 2H), 4.52 (m, 2H), 3.86–3.71 (m, 1H), 3.70–3.26 (m, 2H), 2.79 (s, 3H), 2.31 (m, 2H),

2.18 (m, 2H), 1.78 (m, 2H). ¹³C NMR (101 MHz, D₂O) δ 171.0, 169.3, 163.3 (d, *J*_{C-F} = 243.7 Hz), 158.4 (d, *J*_{C-F} = 11.0 Hz), 130.9 (d, *J*_{C-F} = 10.1 Hz), 111.0 (d, *J*_{C-F} = 2.9 Hz), 109.0 (d, *J*_{C-F} = 21.3 Hz), 102.9 (d, *J*_{C-F} = 25.4 Hz), 95.51, 63.8, 61.5, 60.0, 52.1, 36.9, 25.9, 12.7. HRMS (ESI): calcd for C₁₇H₂₂FN₂O₃ [M + H]⁺, 321.1609; found, 321.1613.

***N*-(2-((5-((4-Fluorophenoxy)methyl)isoxazol-3-yl)oxy)ethyl)-*N*-methylcyclobutanamine hydrochloride (18).** This compound was obtained from **16** employing methods D, E and F. White solid; yield 37%; purity 98.9%. ¹H NMR (400 MHz, D₂O) δ 7.09 (t, *J* = 7.6 Hz, 2H), 7.02 (s, 2H), 6.32 (s, 1H), 5.14 (s, 2H), 4.59 (m, 2H), 3.93–3.78 (m, 1H), 3.56 (m, 2H), 2.88 (s, 3H), 2.38 (m, 2H), 2.27 (m, 2H), 1.87 (m, 1H). ¹³C NMR (101 MHz, D₂O) δ 171.0, 169.5, 157.8 (d, *J*_{C-F} = 237.5 Hz), 153.3 (d, *J*_{C-F} = 2.0 Hz), 116.7 (d, *J*_{C-F} = 8.4 Hz), 116.1 (d, *J*_{C-F} = 23.5 Hz), 95.5, 63.8, 62.0, 60.0, 52.1, 37.0, 26.1, 25.7, 12.7. HRMS (ESI): calcd for C₁₇H₂₂FN₂O₃ [M + H]⁺, 321.1609; found, 321.1597.

***N*-(2-((5-((3-Bromophenoxy)methyl)isoxazol-3-yl)oxy)ethyl)-*N*-methylcyclobutanamine hydrochloride (19).** This compound was obtained from **16** employing methods D, E and F. White solid; yield 36%; purity 98.1%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.49 (br, 1H), 7.28 (d, *J* = 9.2 Hz, 2H), 7.19 (d, *J* = 7.6 Hz, 1H), 7.07 (d, *J* = 8.0 Hz, 1H), 6.48 (s, 1H), 5.25 (s, 2H), 4.59 (m, 2H), 3.76 (m, 1H), 3.58–3.39 (m, 2H), 2.67 (s, 3H), 2.37 (m, 2H), 2.23–2.09 (m, 2H), 1.67 (m, 2H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 170.6, 168.7, 158.3, 131.3, 124.3, 122.1, 117.6, 114.2, 95.6, 64.2, 60.8, 58.6, 50.6, 36.5, 25.3, 24.9, 12.6. HRMS (ESI): calcd for C₁₇H₂₂BrN₂O₃ [M + H]⁺, 381.0808; found, 381.0800.

***N*-(2-((5-((4-Bromophenoxy)methyl)isoxazol-3-yl)oxy)ethyl)-*N*-methylcyclobutanamine hydrochloride (20).** This compound was obtained from **16** employing methods D, E and F. White solid; yield 44%; purity 95.9%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.28 (br, 1H), 7.47 (d, *J* = 8.4 Hz, 2H), 7.01 (d, *J* = 8.4 Hz, 2H), 6.45 (s, 1H), 5.19 (s, 2H), 4.65–4.48 (m, 2H), 3.74 (m, 1H), 3.42 (m, 2H), 2.65 (s, 3H), 2.42–2.25 (m, 2H), 2.22–2.08 (m, 2H), 1.67 (m, 2H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 170.5, 168.7, 156.6, 132.1, 117.0, 112.9, 95.5, 64.1, 60.7, 58.6, 50.6, 36.5, 25.3, 24.8, 12.7. HRMS (ESI): calcd for C₁₇H₂₂BrN₂O₃ [M + H]⁺, 381.0808; found, 381.0789.

***N*-(2-((5-((3,4-Difluorophenoxy)methyl)isoxazol-3-yl)oxy)ethyl)-*N*-methylcyclobutanamine hydrochloride (21).** This compound was obtained from **16** employing methods D, E and F. White solid; yield 41%; purity 98.1%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.20 (br, 1H), 7.39 (q, *J* = 9.6 Hz, 1H), 7.28–7.17 (m, 1H), 6.95–6.84 (m, 1H), 6.48 (s, 1H), 5.21 (s, 2H), 4.57 (m, 2H), 3.76 (m, 1H), 3.44 (m, 2H), 2.67 (s, 3H), 2.32 (m, 2H), 2.25–2.02 (m, 2H), 1.70 (m, 2H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 170.6, 168.6, 153.9 (d, *J*_{C-F} = 9.2 Hz), 149.5 (dd, *J*_{C-F} = 245.3, 13.7 Hz), 144.4 (dd, *J*_{C-F} = 238.6, 12.8 Hz), 117.7 (d, *J*_{C-F} = 18.4 Hz), 111.2 (dd, *J*_{C-F} = 6.1, 3.2 Hz), 104.6 (d, *J*_{C-F} = 20.5 Hz), 95.7, 64.2, 61.3, 58.7, 50.7, 36.6, 25.4, 24.9, 12.6. HRMS (ESI): calcd for C₁₇H₂₁F₂N₂O₃ [M + H]⁺, 339.1515; found, 339.1497.

***N*-(2-((5-((3,5-Difluorophenoxy)methyl)isoxazol-3-yl)oxy)ethyl)-*N*-methylcyclobutanamine hydrochloride (22).** This compound was obtained from **16** employing methods D, E and F. White solid; yield 52%; purity 100%. ¹H NMR (400 MHz, CDCl₃) δ 6.42 (m, 3H), 5.95 (s, 1H), 4.96 (s, 2H), 4.29 (t, *J* = 6.4 Hz, 2H), 2.89–



2.75 (m, 1H), 2.63 (t, $J = 6.4$ Hz, 2H), 2.15 (s, 3H), 2.05–1.93 (m, 2H), 1.91–1.77 (m, 2H), 1.68–1.50 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.7, 167.3, 163.6 (dd, $J_{\text{C-F}} = 247.4$, 15.5 Hz), 159.5 (t, $J_{\text{C-F}} = 13.6$ Hz), 98.7 (dd, $J_{\text{C-F}} = 20.6$, 8.4 Hz), 97.4 (t, $J_{\text{C-F}} = 25.8$ Hz), 95.5, 67.8, 61.9, 60.5, 52.5, 38.5, 27.7, 13.8. HRMS (ESI): calcd for $\text{C}_{17}\text{H}_{21}\text{F}_2\text{N}_2\text{O}_3$ $[\text{M} + \text{H}]^+$, 339.1515; found, 339.1513.

***N*-(2-((5-((3,4-Dichlorophenoxy)methyl)isoxazol-3-yl)oxy)ethyl)-*N*-methylcyclobutanamine hydrochloride (23).** This compound was obtained from **16** employing methods D, E and F. White solid; yield 45%; purity 99.3%. ^1H NMR (400 MHz, D_2O) δ 7.24 (d, $J = 6.4$ Hz, 1H), 6.95 (s, 1H), 6.81 (d, $J = 8.0$ Hz, 1H), 6.28 (s, 1H), 5.00 (s, 2H), 4.57 (m, 2H), 3.82 (m, 1H), 3.54 (m, 2H), 2.86 (s, 3H), 2.31 (m, 4H), 1.80 (m, 2H). ^{13}C NMR (101 MHz, D_2O) δ 170.8, 168.6, 156.5, 132.4, 130.8, 124.6, 116.8, 114.5, 95.7, 63.9, 61.5, 59.9, 52.0, 37.2, 26.0, 12.8. HRMS (ESI): calcd for $\text{C}_{17}\text{H}_{21}\text{Cl}_2\text{N}_2\text{O}_3$ $[\text{M} + \text{H}]^+$, 371.0924; found, 371.0920.

***N*-(2-((5-((3, 5-Dichlorophenoxy)methyl)isoxazol-3-yl)oxy)ethyl)-*N*-methylcyclobutanamine hydrochloride (24).** This compound was obtained from **16** employing methods D, E and F. White solid; yield 40%; purity 99.1%. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.04 (br, 1H), 7.22 (s, 1H), 7.18 (s, 2H), 6.49 (s, 1H), 5.28 (s, 2H), 4.57 (m, 2H), 3.76 (m, 1H), 3.49 (m, 2H), 2.67 (s, 3H), 2.31 (m, 2H), 2.18 (m, 2H), 1.68 (m, 2H). ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 170.6, 168.3, 158.7, 134.7, 121.3, 114.2, 95.9, 64.2, 61.1, 58.7, 50.8, 36.6, 25.4, 25.0, 12.6. HRMS (ESI): calcd for $\text{C}_{17}\text{H}_{21}\text{Cl}_2\text{N}_2\text{O}_3$ $[\text{M} + \text{H}]^+$, 371.0924; found, 371.0923.

***N*-(2-((5-((3-Chloro-4-fluorophenoxy)methyl)isoxazol-3-yl)oxy)-ethyl)-*N*-methylcyclobutanamine hydrochloride (25).** This compound was obtained from **16** employing methods D, E and F. White solid; yield 37%; purity 97.4%. ^1H NMR (400 MHz, CDCl_3) δ 7.02 (t, $J = 8.8$ Hz, 1H), 6.95 (dd, $J = 5.8$, 3.0 Hz, 1H), 6.77 (m, 1H), 5.94 (s, 1H), 4.95 (s, 2H), 4.29 (t, $J = 5.8$ Hz, 2H), 2.88–2.77 (m, 1H), 2.64 (t, $J = 5.8$ Hz, 2H), 2.15 (s, 3H), 2.05–1.92 (m, 2H), 1.91–1.75 (m, 2H), 1.62 (m, 2H). ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 170.6, 168.6, 154.0 (d, $J_{\text{C-F}} = 2.2$ Hz), 152.3 (d, $J_{\text{C-F}} = 239.8$ Hz), 119.8 (d, $J_{\text{C-F}} = 19.1$ Hz), 117.3 (d, $J_{\text{C-F}} = 22.5$ Hz), 116.5, 115.4 (d, $J_{\text{C-F}} = 7.0$ Hz), 95.7, 64.2, 61.3, 58.6, 50.6, 36.5, 25.3, 24.8, 12.6. HRMS (ESI): calcd for $\text{C}_{17}\text{H}_{21}\text{ClFN}_2\text{O}_3$ $[\text{M} + \text{H}]^+$, 355.1219; found, 335.1220.

***N*-Methyl-*N*-(2-((5-((3-(trifluoromethyl)phenoxy)methyl)isoxazol-3-yl)oxy)ethyl)cyclobutanamine hydrochloride (26).** This compound was obtained from **16** employing methods D, E and F. White solid; yield 46%; purity 96.4%. ^1H NMR (400 MHz, D_2O) δ 7.19 (d, $J = 7.2$ Hz, 1H), 6.98 (m, 3H), 6.14 (s, 1H), 4.91 (s, 2H), 4.46 (m, 2H), 3.68 (m, 1H), 3.42 (m, 2H), 2.75 (s, 3H), 2.29–2.15 (m, 4H), 1.68 (m, 2H). ^{13}C NMR (101 MHz, D_2O) δ 170.8, 168.8, 157.4, 131.2 (q, $J_{\text{C-F}} = 32.2$ Hz), 130.4, 123.7 (q, $J_{\text{C-F}} = 272.1$ Hz), 118.2 (d, $J_{\text{C-F}} = 3.8$ Hz), 117.9, 111.8 (q, $J_{\text{C-F}} = 4.0$ Hz), 95.5, 63.8, 61.1, 59.9, 52.0, 37.1, 25.9, 12.6. HRMS (ESI): calcd for $\text{C}_{18}\text{H}_{22}\text{F}_3\text{N}_2\text{O}_3$ $[\text{M} + \text{H}]^+$, 371.1577; found, 371.1565.

***N*-Methyl-*N*-(2-((5-((*m*-tolyl)oxy)methyl)isoxazol-3-yl)oxy)ethyl)-cyclobutanamine hydrochloride (27).** This compound was obtained from **16** employing methods D, E and F. White solid; yield 51%. Purity 98.2%. ^1H NMR (400 MHz, D_2O) δ 7.18 (t, $J = 7.8$ Hz, 1H), 6.84 (d, $J = 7.2$ Hz, 1H), 6.81–6.74 (m, 2H), 6.22 (s, 1H), 5.05 (s, 2H), 4.48 (m, 2H), 3.77 (m, 1H), 3.46 (m, 2H), 2.77

(s, 3H), 2.29 (m, 2H), 2.21 (s, 3H), 2.17 (m, 2H), 1.76 (m, 2H). ^{13}C NMR (101 MHz, D_2O) δ 171.0, 169.7, 157.2, 140.5, 129.7, 123.1, 115.8, 112.0, 95.4, 63.7, 61.2, 60.0, 52.1, 36.9, 25.9, 20.5, 12.7. HRMS (ESI): calcd for $\text{C}_{18}\text{H}_{25}\text{N}_2\text{O}_3$ $[\text{M} + \text{H}]^+$, 317.1860; found, 317.1866.

***N*-(2-((5-(Phenoxymethyl)isoxazol-3-yl)oxy)ethyl)cyclobutanamine hydrochloride (28).** This compound was obtained from **15** employing methods D, E and F. White solid; yield 27%; purity 94.6%. ^1H NMR (400 MHz, CDCl_3) δ 7.30 (t, $J = 8.0$ Hz, 2H), 7.00 (t, $J = 7.4$ Hz, 1H), 6.94 (d, $J = 8.0$ Hz, 2H), 5.98 (s, 1H), 5.04 (s, 2H), 4.33 (t, $J = 5.2$ Hz, 2H), 3.44–3.26 (m, 1H), 2.96 (t, $J = 5.2$ Hz, 2H), 2.54 (br, 1H), 2.32–2.16 (m, 2H), 1.88–1.51 (m, 4H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.7, 168.9, 157.7, 129.6, 121.9, 114.8, 94.9, 69.2, 61.6, 53.9, 45.6, 30.7, 14.7. HRMS (ESI): calcd for $\text{C}_{16}\text{H}_{21}\text{N}_2\text{O}_3$ $[\text{M} + \text{H}]^+$, 289.1560; found, 289.1547.

***N*-(2-((5-((3-Chlorophenoxy)methyl)isoxazol-3-yl)oxy)ethyl)-cyclobutanamine hydrochloride (29).** This compound was obtained from **15** employing methods D, E and F. White solid; yield 55%; purity 96.7%. ^1H NMR (400 MHz, CDCl_3) δ 7.19 (t, $J = 8.2$ Hz, 1H), 6.97 (d, $J = 8.0$ Hz, 1H), 6.93 (s, 1H), 6.81 (dd, $J = 8.2$, 1.8 Hz, 1H), 5.96 (s, 1H), 4.99 (s, 2H), 4.29 (t, $J = 4.0$ Hz, 2H), 3.34–3.21 (m, 1H), 2.91 (t, $J = 4.0$ Hz, 2H), 2.26–2.12 (m, 2H), 1.75–1.57 (m, 4H), 1.51 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.7, 168.1, 158.4, 135.1, 130.4, 122.1, 115.4, 113.1, 95.1, 69.8, 61.7, 54.0, 45.7, 31.2, 14.7. HRMS (ESI): calcd for $\text{C}_{16}\text{H}_{20}\text{ClN}_2\text{O}_3$ $[\text{M} + \text{H}]^+$, 323.1157; found, 323.1171.

***N*-Cyclobutyl-*N*-(2-((5-(phenoxymethyl)isoxazol-3-yl)oxy)ethyl)-cyclobutanamine hydrochloride (30).** This compound was obtained from **15** employing methods D, E and F. White solid; yield 24%; purity 98.4%. ^1H NMR (400 MHz, CDCl_3) δ 7.29 (t, $J = 8.0$ Hz, 2H), 6.99 (t, $J = 7.4$ Hz, 1H), 6.94 (d, $J = 8.0$ Hz, 2H), 5.96 (s, 1H), 5.02 (s, 2H), 4.25 (t, $J = 6.2$ Hz, 2H), 3.28–3.14 (m, 2H), 2.89 (t, $J = 6.2$ Hz, 2H), 2.11–1.85 (m, 8H), 1.72–1.50 (m, 4H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.6, 168.8, 157.7, 129.6, 121.8, 114.8, 94.9, 67.8, 61.6, 57.4, 46.2, 28.8, 15.1. HRMS (ESI): calcd for $\text{C}_{20}\text{H}_{27}\text{N}_2\text{O}_3$ $[\text{M} + \text{H}]^+$, 343.2016; found, 343.2025.

General procedures for vitro binding studies

Radioligand competition studies were carried out by the National Institute of Mental Health's Psychoactive Drug Screening Program, Contract #HHSN-271-2008-00025-C (NIMH PDSP). The general procedures are listed as follows:

All the test compounds solution (1 mg mL^{-1}) were prepared by dissolving in DMSO or buffer solvent (50 mM Tris-HCl, pH = 8.0). The filter-mats were presoaked in 0.5% aqueous polyethyleneimine solution for 2 h at rt before use. All binding experiments were carried out in poly-L-lysine-coated 96-well plate and the final test concentration (50 μM , 5 μM , 1.5 μM , 500 nM, 150 nM, 50 nM, 15 nM, 5 nM, 1.5 nM, 0.5 nM, 0.05 nM) were prepared by addition of Tris-HCl solution (50 mM, pH = 8.0). The following specific radioligands and tissue source were used: (a) σ_1 receptor, [^3H]-(+)-pentazocine, Guinea pig brain homogenate; (b) σ_2 receptor, [^3H]-DTG, PC-12 cells. 100 μL of corresponding radioligand solution, 100 μL test compound solution and 50 μL of the respective receptor preparation into



each well of the plate (total volume 250 μ L). During the incubation, the plates were shaken at a speed of 500–600 rpm at the specified temperature (σ 1 receptor, 37 $^{\circ}$ C, 150 min; σ 2 receptor, rt, 120 min). The incubation was followed by a rapid vacuum filtration through Whatman GF/B glass filters, and the filtrates were washed twice with 10 mL of cold buffer and transferred to the 6 mL scintillation vials. EcoScint scintillation fluid (4.0 mL) was added, and the radioactivity bound was measured using a Beckman LS 6500 liquid scintillation counter. All experiments were performed at least three times.

For experimental details please refer to the PDSP website <http://pdsp.med.unc.edu/>.²⁸

General procedures for cellular evaluation

NGF-induced neurite outgrowth in PC-12 cells. PC-12 cells, from rat pheochromocytoma cell lines, were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Undifferentiated PC12 cells were cultured in DMEM complete medium with 10% heat-inactivated horse serum, 5% fetal bovine serum, 100 U mL⁻¹ penicillin, and 100 μ g mL⁻¹ streptomycin and maintained at 37 $^{\circ}$ C in a humidified incubator supplemented with 5% CO₂. To induce differentiation, PC12 cells were seeded at a density of 1×10^4 cells per mL on a poly-L-lysine-coated 96-well plate and cultured in complete medium containing 2.5 ng mL⁻¹ NGF or different tested compounds (10 μ M) concomitant with 2.5 ng mL⁻¹ NGF administration. Four days after incubation, morphometric analysis was performed on digitized images of live cells taken under phase contrast illumination with an inverted microscope linked to a camera. Images of five fields per well were taken with an average of 20 cells per field. The number of differentiated cells was determined by counting cells that had at least one neurite with a length equal to the cell body diameter and was expressed as a percentage of the total cells in the field. The counting was performed in a blinded manner. All experiments were performed at least five times.

Neurite outgrowth in N1E-115 cells. N1E-115 cells, the mouse neuroblastoma cell lines, were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Undifferentiated N1E115 cells were cultured in DMEM complete medium with 10% fetal bovine serum, 100 U mL⁻¹ of penicillin, and 100 μ g mL⁻¹ of streptomycin and maintained at 37 $^{\circ}$ C in a humidified incubator supplemented with 5% CO₂. N1E-115 cells were seeded at a density of 1×10^4 cells per mL on poly-L-lysine-coated 96-well plates and grown with DMSO or different tested compounds (10 μ M) in DMSO solution for four days. Four days after incubation, morphometric analysis was performed on digitized images of live cells taken under phase contrast illumination with an inverted microscope linked to a camera. Images of five fields per well were taken with an average of 100 cells per field. Cells that had at least one neurite with a length that was twice as long as the body diameter were expressed as a percentage of the total cells in the field. The counting was performed in a blinded manner. All experiments were performed at least five times.

Positive control drugs. Compounds RC-33 (5) and compound 7 were synthesized according to procedures described in literatures.^{23,24,27}

RC-33(5). White solid; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.36 (s, 1H), 7.64 (m, 4H), 7.46 (t, *J* = 7.6 Hz, 2H), 7.36 (d, *J* = 8.1 Hz, 3H), 3.03 (m, 2H), 2.88–2.68 (m, 4H), 2.06 (m, 2H), 1.72 (m, 6H), 1.43–1.28 (m, 1H), 1.25 (d, *J* = 6.9 Hz, 3H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 144.9, 139.9, 138.2, 128.9, 127.4, 127.2, 126.8, 126.5, 54.7, 51.8, 51.8, 36.7, 30.7, 22.3, 21.4.

Compound 7. White solid; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.99 (s, 1H), 7.36–7.28 (m, 2H), 7.03 (d, *J* = 8.0 Hz, 2H), 6.99 (t, *J* = 8.0 Hz, 1H), 6.45 (s, 1H), 5.19 (s, 2H), 4.56 (m, 2H), 3.81–3.68 (m, 1H), 2.67 (s, 3H), 2.38–2.24 (m, 2H), 2.17 (m, 2H), 1.68 (m, 2H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 170.9, 169.6, 157.0, 129.9, 122.3, 115.0, 95.4, 63.6, 61.1, 59.9, 52.0, 36.8, 25.9, 12.6.

Conflicts of interest

There are no conflicts of interest to declare.

Abbreviations

AD	Alzheimer's disease
PD	Parkinson's disease
ALS	Amyotrophic lateral sclerosis
HD	Huntington's disease
CNS	Central nervous system
ER	Endoplasmic reticulum
NMDA	<i>N</i> -Methyl-D-aspartate
IP ₃	Inositol 1,4,5-trisphosphate
NGF	Nerve growth factor
SAR	Structure–activity relationship
NIMH-	National Institute of Mental Health-Psychoactive
PDSP	Drug Screening Program
CNS MPO	Central nervous system multiparameter optimization
DAT	Dopamine transporter
NET	Norepinephrine transporter
SERT	Serotonin transporter
CC	Column chromatography
rt	Room temperature

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81402780), the Natural Science Foundation of Shanghai (14ZR1411000), the Natural Science Foundation of Jiangsu Province (BK20160032), and Innovation Program of East China Normal University (78210263). We thank the PDSP for performing binding affinity assays. We thank Dr Hendra Gunosewoyo for proofreading the manuscript.

References

- 1 I. Solanki, P. Parihar and M. S. Parihar, *Neurochem. Int.*, 2016, **95**, 100–108.



- 2 J. Hardy, *Ann. N. Y. Acad. Sci.*, 1999, **74**, 835–837.
- 3 U. Dirnagl, *Ann. N. Y. Acad. Sci.*, 2012, **1268**, 21–25.
- 4 V. Francardo, Y. Schmitz, D. Sulzer and M. A. Cenci, *Exp. Neurol.*, 2017, **298**, 137–147.
- 5 T. Wieloch and K. Nikolic, *Curr. Opin. Neurobiol.*, 2006, **16**, 258–264.
- 6 S. Kourrich, T. P. Su, M. Fujimoto and A. Bonci, *Trends Neurosci.*, 2012, **35**, 762–771.
- 7 W. R. Martin, C. G. Eades, J. A. Thompson, R. E. Huppler and P. E. Gilbert, *J. Pharmacol. Exp. Ther.*, 1976, **197**, 517–532.
- 8 M. Hanner, F. F. Moebius, A. Flandorfer, H. G. Knaus, J. Striessnig, E. Kempner and H. Glossmann, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **93**, 8072–8077.
- 9 T. Hayashi, R. Rizzuto, G. Hajnoczky and T. P. Su, *Trends Cell Biol.*, 2009, **19**, 81–88.
- 10 H. R. Schmidt, S. D. Zheng, E. Gurpinar, *et al.*, *Nature*, 2016, **532**, 527–530.
- 11 T. Hayashi and T. P. Su, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 491–496.
- 12 T. Hayashi and T. P. Su, *Cell*, 2007, **131**, 596–610.
- 13 T. Hayashi, *J. Pharmacol. Sci.*, 2015, **127**, 2–5.
- 14 M. V. Sofroniew, *Trends Neurosci.*, 2009, **32**, 638–647.
- 15 T. P. Su, T. Hayashi, T. Maurice, S. Buch and A. E. Ruoho, *Trends Pharmacol. Sci.*, 2010, **31**, 557–566.
- 16 K. Ruscher, M. Shamloo, M. Rickhag, *et al.*, *Brain*, 2011, **134**, 732–746.
- 17 M. Pabba, A. Y. Wong, N. Ahlskog, *et al.*, *J. Neurosci.*, 2014, **34**, 11325–11338.
- 18 M. Fujimoto, T. Hayashi, R. Urfer, S. Mita and T. P. Su, *Synapse*, 2012, **66**, 630–639.
- 19 S. Sha, W. J. Qu, L. Li, Z. H. Lu, L. Chen, W. F. Yu and L. Chen, *CNS Neurosci. Ther.*, 2013, **19**, 705–713.
- 20 M. Takebayashi, T. Hayashi and T. P. Su, *Synapse*, 2004, **53**, 90–103.
- 21 T. Ishima, T. Nishimura, M. Iyo and K. Hashimoto, *Prog. Neuro-Psychopharmacol. Biol. Psychiatry*, 2008, **32**, 1656–1659.
- 22 R. Mancuso, S. Oliván, A. Rando, *et al.*, *Neurotherapeutics*, 2012, **9**, 814–826.
- 23 D. Rossi, A. Pedrali, M. Urbano, R. Gaggeri, S. Collina, *et al.*, *Bioorg. Med. Chem.*, 2011, **19**, 6210–6224.
- 24 D. Rossi, A. Marra, P. Picconi, S. Pricl, S. Collina, *et al.*, *Bioorg. Med. Chem.*, 2013, **21**, 2577–2586.
- 25 A. Marra, D. Rossi, L. Pignataro, S. Collina, *et al.*, *Future Med. Chem.*, 2016, **8**, 287–295.
- 26 S. Collina, M. Rui, G. Rossino, S. D. Volpe, *et al.*, *Future Med. Chem.*, 2017, **9**, 2029–2051.
- 27 H. Sun, M. Shi, W. Zhang, L. F. Yu, *et al.*, *J. Med. Chem.*, 2016, **59**, 6329–6343.
- 28 K_i determinations were generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program, contract no. HHSN-271-2008-00025-C (NIMH PDSP). The NIMH PDSP is directed by Bryan L. Roth MD, PhD, at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda, MD, USA.
- 29 T. T. Wager, R. Y. Chandrasekaran, X. Hou, *et al.*, *ACS Chem. Neurosci.*, 2010, **1**, 420–434.
- 30 T. T. Wager, X. Hou, P. R. Verhoest, *et al.*, *ACS Chem. Neurosci.*, 2016, **7**, 767–775.
- 31 P. N. M. Konings, *Neurosci. Lett.*, 1994, **178**, 115–118.
- 32 S. Chang, W. C. Ruan, Y. Z. Xu, H. Liao, T. Pang, *et al.*, *Acta Pharmacol. Sin.*, 2017, **38**, 29–40.
- 33 L. F. Yu, H. K. Zhang, H. Gunosewoyo and A. P. Kozikowski, *ACS Med. Chem. Lett.*, 2012, **3**, 1054–1058.

